BD Receives the US FDA’s Clearance for Infectious Vaginitis Test for Use in High Throughput Platform
Shots:
- The US FDA has granted 510(k) clearance to the BD Vaginal Panel to detect multiple common types of vaginitis on the BD COR system, a high throughput analytical system using 1 swab, one test in large laboratories
- The BD COR system is the PCR assay that can detect organisms linked to bacterial vaginosis, vulvovaginal candidiasis (VVC), and Trichomonas vaginalis & provides accurate and reliable results. The BD Vaginal Panel is the third assay available for use on the BD COR System in the US
- A single test can help to reduce the need for additional testing, avoidable treatment use & risk of contracting STIs. The BD Vaginal Panel, the only US FDA-cleared NAAT that provides separate results for two Candida species
Ref: PRNewswire | Image: BD
Related News:- Biocon Entered into an Out-Licensing Agreement with Yoshindo to Commercialize bUstekinumab and bDenosumab in the Japan
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
